Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
REVIEW PAPER
Diabetes – the history of research and treatment
1
Clinic of Endocrinology, Diabetology and Internal Medicine, Department of Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2018-06-18
Final revision date: 2019-11-24
Acceptance date: 2019-11-24
Online publication date: 2020-03-19
Corresponding author
Angelika Baranowska-Jurkun
1. Department of Internal Medicine, Endocrinology and Diabetology Clinic, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn
1. Department of Internal Medicine, Endocrinology and Diabetology Clinic, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn
Pol. Ann. Med. 2020;27(1):78-84
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The history of diabetes is a fascinating journey – from the times before the current era to the modern day. This history is rich in a lot of discoveries, advancements in science and technology, renowned scientists, doctors and their achievements as well as challenges.
Aim:
To present the history of research on diabetes and its treatment.
Material and methods:
A review of literature concerning the history of research on diabetes and methods of its treatment.
Results and discussion:
First descriptions of diabetes, today a well-known disease, date back to ancient Egypt; its mysteries were discovered by Hippocrates, Aretaeus of Cappadocia and an Arabic doctor Avicenna. The term ‘diabetes mellitus’ was first used in 1797 and the greatest breakthrough in research on diabetes took place in 1922, when insulin was discovered. This revolutionised the treatment, yet led to the development of a number of chronic vascular complications.
Conclusions:
At present, diabetes – as a non-communicable disease – is perceived by the World Health Organisation as an epidemics, and only getting to know its history can mean having complete knowledge about the disease.
The history of diabetes is a fascinating journey – from the times before the current era to the modern day. This history is rich in a lot of discoveries, advancements in science and technology, renowned scientists, doctors and their achievements as well as challenges.
Aim:
To present the history of research on diabetes and its treatment.
Material and methods:
A review of literature concerning the history of research on diabetes and methods of its treatment.
Results and discussion:
First descriptions of diabetes, today a well-known disease, date back to ancient Egypt; its mysteries were discovered by Hippocrates, Aretaeus of Cappadocia and an Arabic doctor Avicenna. The term ‘diabetes mellitus’ was first used in 1797 and the greatest breakthrough in research on diabetes took place in 1922, when insulin was discovered. This revolutionised the treatment, yet led to the development of a number of chronic vascular complications.
Conclusions:
At present, diabetes – as a non-communicable disease – is perceived by the World Health Organisation as an epidemics, and only getting to know its history can mean having complete knowledge about the disease.
FUNDING
None declared.
CONFLICT OF INTEREST
None declared.
REFERENCES (82)
1.
Henschen F. On the term Diabetes In the Works of Aretaeus and Galen. Med Hist. 1969;13(2):190–192. https://dx.doi.org/10.1017%2Fs....
2.
Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991–1998. JAMA. 1999;282(16):1519–1522. https://doi.org/10.1001/jama.2....
3.
Hu FB. Globalization of diabetes. The role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–1257. https://doi.org/10.2337/dc11-0....
4.
Rollo J, Cruickshank W. An Account of Two Cases of the Diabetes Mellitus, with Remarks as They Arose During the Progress of the Cure. London: T. Gillet; 1797.
6.
von Mering J, Minkowski O. Diabetes mellitus nach Pancreasextirpation. Arch Exper Path Pharm Leipzig. 1890;26:371–387.
8.
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J. 1922;12(3):141–146.
10.
Markel H. How a Boy Became the First to Beat Back Diabetes. 2013. https://www.pbs.org/newshour/h.... Accessed: May 31, 2018.
11.
Grott JW, Wiesbaum S. Windyga S. [Insulin in Poland compared to foreigners]. Pol Gazeta Lek. 1929;8(50):941–948 [in Polish].
12.
Czupryniak L, Loba J. Protamine insulin in Poland. In: Deckert T, ed. Hagedorn. Łódź: PTBPC. 2004;299–316.
13.
Scherntthanger G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care. 1998;21(4):570–573. https://doi.org/10.2337/diacar....
14.
Mathiesen ER. Insulin aspart in diabetic pregnancy: state of the art. Womens Health. 2008;4(2):119–124. https://doi.org/10.2217/174550....
15.
Helms KL, Kelly KW. Insulin glulisine: an evaluation of its pharmacodynamics properties and clinical application. Ann Pharmacother. 2009;43(4):658-668. https://doi.org/10.1345/aph.1E....
16.
Bandurska-Stankiewicz E, Matuszewski W. [The importance of insulin analogues to treat patients with diabetes]. Med Metabol. 2011;15(3):95–96 [in Polish].
17.
McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs. 2001;61(11):1599–1624. https://doi.org/10.2165/000034....
18.
Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–950. https://doi.org/10.1111/j.1463....
19.
Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400. https://doi.org/10.2147/TCRM.S....
20.
Zhou W, Tao J, Zhou X, Chen H. Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019;10(3):835–852. https://doi.org/10.1007/s13300....
21.
Szendzielorz-Honisz K, Strojek K. Diabetology. A Practical Guide. Poznań: Termedia. 2008;6:62.
22.
Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082. https://doi.org/10.1210/jcem-2....
23.
Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–136. https://www.researchgate.net/d....
24.
Nauck MA, Homberger E, Siegel E et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492–498. https://doi.org/10.1210/jcem-6....
25.
Baranowska A, Stefanowicz-Rutkowska M, Matuszewski W, Bandurska-Stankiewicz E. [New antidiabetic drugs: current status and future prospects – a review of the literature]. Wiad Lek. 2018;71(8):1588–1598 [in Polish].
26.
Ehrenkranz RRL, Lewis NG, Kahn CR, Roth J. Phlorizin: Areview. Diabetes Metab Res Rev. 2005;21(1):31–38. https://doi.org/10.1002/dmrr.5....
27.
Marble A. Insulin-clinical aspects: The first fifty years. Diabetes. 1972;21(2):632–636. https://doi.org/10.2337/diab.2....
28.
Matuszewski W, Bandurska-Stankiewicz E, Wiatr-Bykowska D, Myszka-Podgórska K, Kamińska U. Diabetic Neuropathy. Pol Ann Med. 2013;20(2):154–159. https://doi.org/10.1016/j.poam....
29.
Gromadziński L, Januszko-Giergielewicz B, Lipińska A, Pruszczyk P. Effect of type 2 diabetes on the left ventricular diastolic dysfunction in patients with chronic kidney disease, 3 and 4 stages. Pol Ann Med. 2014;21(1):8–13. https://doi.org/10.1016/j.poam....
30.
Gomes MB, Almeida AP, Santos DC, et al. Cause-specific mortality in a cohort of Brazilian patients with type 1 diabetes. Acta Diabetol. 2017;54(6):535–542. https://doi.org/10.1007/s00592....
31.
Rewers A, Coakley A, Pyle L, et al. Increasing prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children. In: 55th EASD Annual Meeting of the Association for the Study of Diabetes: Barcelona, Spain, 16–20 September 2019. Diabetologia. 2019;62(Suppl 1):62. https://doi.org/10.1007/s00125....
32.
WHO. Global report on diabetes. 2016. http://www.who.int/diabetes/gl.... Accessed: May 31, 2018.
33.
Grzeszczak W. [Diabetic eye disease]. In: Sieradzki J, ed. [Diabetology – Compendium]. Gdańsk: Via Medica. 2009;15:368 [in Polish].
34.
Sigerist HE. A history of medicine. Vol. 2: Early Greek, Hindu and Persian medicine. New York: Oxford University Press; 1951.
36.
Kimmelsteil P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12(1):83–97.
37.
Mogensen CE. Microlabuminuria. A marker for organ damage. London: Science Press; 1996.
38.
Czekalski S. [Diabetic nephropathy or diabetic kidney disease?]. Forum Nefrol. 2008;1(2):53–56.
39.
Mogensen CE, Christiansen CK, Vittinghus E. The stages in diabetic renal disease: With emphasis on stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78. https://doi.org/10.2337/diab.3....
40.
KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(Suppl 2):S12–S154.
41.
American Diabetes Association. Microvascular complications and foot care. Diabetes Care. 2017;40(Suppl 1):S88–S98. https://doi.org/10.2337/dc17-S....
42.
Thorn LM, Gordin D, Harjutsalo V, at al. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2015;38(11):2128–2133. https://doi.org/10.2337/dc15-0....
43.
Rossing P, Persson F, Frimodt-Møller M. Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. Néphrol Thér. 2018;14(Suppl 1):31–37. https://doi.org/10.1016/j.neph....
44.
Forsblom C, Moran J, Harjutsalo V, et al. Added value of soluble tumor necrosis factor-α receptor-1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care. 2014;37(8):2334–2342. https://doi.org/10.2337/dc14-0....
45.
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2....
46.
Witek P. [Diabetic autonomic neuropathy]. In: Sieradzki J, ed. [Diabetes]. Vol. 2. Gdańsk: Via Medica; 2016:650.
47.
Rollo M. An account of two cases of the diabetes mellitus, with remarks as they arose during the progress of the cure. London: C. Dilly 1806.
48.
Martin MM. Diabetic neuropathy: A clinical study of 150 cases. Brain. 1953;76(4):594–624. https://doi.org/10.1093/brain/....
49.
Pavy FW. Introductory address to the discussion on the clinical aspect of glycosuria. Lancet. 1885;126(3250):1085–1087. https://doi.org/10.1016/S0140-....
51.
Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus Statement. Diabetes Care. 1988;37(7):1000–1004. https://doi.org/10.2337/diacar....
52.
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. https://doi.org/10.2337/dc10-1....
53.
Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American, Academy of Neurology. Diabetes Care 1988;11(7):592–597. https://doi.org/10.2337/diacar....
54.
Watkins PJ. Progression of diabetic autonomic neuropathy. Diabet Med. 1993;10(Suppl 2):77S–78S. https://doi.org/10.1111/j.1464....
55.
Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. J Diabetes Investig. 2018;9(6):1239–1254. https://doi.org/10.1111/jdi.12....
56.
Grenfell A. History of diabetic complications. In: Mogensen CE, Standl E, ed. Prevention and treatment of diabetic late complications. Vol. 2. New York: de Grutyrer; 1989:1–4.
58.
von Graefe A. Ueber die mit diabetes mellitus vorkommenden Sehstϕrungen. Dies Arch. 1858;4:230–234.
60.
Nettleship E. On oedema or cystic disease of the retina. Roy Ophth Lond Hosp Rep. 1872;7(3):343–351.
62.
Poulsen JE. Features of the history of diabetology. Copenhagen: Munskgaard; 1982:119–124.
63.
Hirschberg J. Hαber diabetische Netzhautentzòndung. Dtsch Med Wochenschr. 1890;13:1181.
64.
Ballantyne AJ, Lowenstein A. Pathology of diabetic retinopathy. Trans Opthal Soc UK. 1944;63:95.
65.
Lundbeak K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;1:377–379. https://doi.org/10.1016/s0140-....
66.
Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(2):283–290. https://doi.org/10.1016/S0278-....
67.
Cunha-Vaz J. Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II–III, randomised controlled trail to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy. EUROCONDOR – EU FP7 Project. Acta Ophthalmol. 2012;90(s249). https://doi.org/10.1111/j.1755....
68.
Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014;41:90–111. https://doi.org/10.1016/j.pret....
69.
Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus. Am J Cardiol. 1987;59(8):750–757. https://doi.org/10.1016/0002-9....
70.
Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2018. Diabetes Care. 2018;41(Suppl 1):86–104. https://doi.org/10.2337/dc18-S....
71.
Lundback K. [Diabetic angiopathy]. Acta Diabetol Lat. 1973;10(2):183–207 [in Italian].
72.
Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5(4):294–315.
73.
Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3(2):463–524. https://doi.org/10.1002/dmr.56....
74.
Bryfogle JW, Bradley RF. The vascular complications of diabetes mellitus. A clinical study. Diabetes. 1957;6(2):159–167. https://doi.org/10.2337/diab.6....
75.
Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med. 1997;14(Suppl 3):S6–S11. https://doi.org/10.1002/(sici)....
76.
de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42(8):926–931. https://doi.org/10.1007/s00125....
77.
Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells. The role protein kinase C and NAD(P)H oxidase activation. Diabetes. 2003:52(11):2795–2804. https://doi.org/10.2337/diabet....
78.
El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205(10):2409–2417. https://doi.org/10.1084/jem.20....
79.
Lind L, Sundström J, Ärnlöv J, Lampa E. Impact of Aging on the Strength of Cardiovascular Risk Factors: A Longitudinal Study Over 40 Years. J Am Heart Assoc. 2018;7(1):1–12. https://doi.org/10.1161/JAHA.1....
80.
Keen H. Saint Vincent and Improving Diabetes Care. Specialist UK Workgroup Reports. Introduction. Diabet Med. 1996;13(9 Suppl 4):S3–5.
81.
Rossi C, Marzano V, Consalvo A, et al. Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice. Acta Diabetol. 2018;55(2):121–129. https://doi.org/10.1007/s00592....
82.
Madonna R, Pieragostino D, Balistreri CR, et al. Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. Vascul Pharmacol. 2018;6:S1537–1891. https://doi.org/10.1016/j.vph.....
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
